根据《上市公司独立董事管理办法》《深圳证券交易所上市公司自律监管指 引第 2 号——创业板上市公司规范运作》及《公司章程》等有关规定，周其林先 生的辞职未导致公司董事会成员低于法定最低人数，辞职报告自送达董事会时生 效。周其林先生的辞职不会影响公司董事会正常运行，亦不会对公司日常经营产 生影响。 周其林先生在任职期间勤勉尽责、独立公正，致力于提高公司的规范运作和 健康发展，凭借自身积累的丰富科研经验，为公司可持续发展提供了诸多宝贵建 议，公司董事会对周其林先生在任职期间为公司及董事会所做出的贡献表示衷心 感谢！ 特此公告。 证券代码：300759 证券简称：康龙化成 公告编号：2024-069 康龙化成（北京）新药技术股份有限公司 关于独立非执行董事辞职的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 康龙化成（北京）新药技术股份有限公司（以下简称"公司"）董事会于 2024 年 11 月 27 日收到独立非执行董事周其林先生提交的书面辞职报告，周其林先生 因中国科学院院士兼职管理的有关规定，需辞去公司第三届董事会独立非执行董 事及董事会战略委员会委员职 ...

证券代码：300759 证券简称：康龙化成 公告编号：2024-071 康龙化成（北京）新药技术股份有限公司 关于追加投资境外参股公司暨关联交易的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、关联交易背景概述 2023 年 10 月 18 日，康龙化成（北京）新药技术股份有限公司（以下简称 "公司"）召开了第三届董事会第三次会议和第三届监事会第三次会议，分别审 议通过了《关于投资参股境外公司暨关联交易的议案》，同意公司以自有资金 1,050 万美元通过全资子公司 Pharmaron (Hong Kong) International Limited（以下 简称"康龙香港国际"）与合作方 CMS MEDICAL VENTURE PTE. LTD.（以下简 称"康哲药业"）、Rxilient Health Pte. Ltd.（以下简称"康联达"）、HEALTHY GOAL LIMITED（以下简称"君联基金"，君联基金和康龙香港国际、康哲药业、康联 达合称"全体投资人"）共同投资位于新加坡的 Rxilient Biohub Pte. Ltd.（现更名 ...

康龙化成（北京）新药技术股份有限公司 章程 （ 2024 年 11 月） 中国 北京 | 第一章 | 总则 1 | | --- | --- | | 第二章 | 经营宗旨和经营范围 2 | | 第三章 | 股份 3 | | 第一节 | 股份发行 3 | | 第二节 | 股份增减和回购 6 | | 第三节 | 股份转让 8 | | 第四章 | 股东和股东大会 10 | | 第一节 | 股东 10 | | 第二节 | 股东大会的一般规定 14 | | 第三节 | 股东大会的召集 21 | | 第四节 | 股东大会的提案与通知 23 | | 第五节 | 股东大会的召开 26 | | 第六节 | 股东大会的表决和决议 31 | | 第七节 | 类别股东表决的特别程序 38 | | 第五章 | 董事会 40 | | 第一节 | 董事 40 | | 第二节 | 董事会 44 | | 第三节 | 独立非执行董事 51 | | 第四节 | 董事会秘书 56 | | 第六章 | 经理及其他高级管理人员 58 | | 第七章 | 监事会 61 | | 第一节 | 监事 61 | | 第二节 | 监事会 62 | | 第八章 | 公 ...

证券代码：300759 证券简称：康龙化成 公告编号：2024-072 康龙化成（北京）新药技术股份有限公司 关于召开 2024 年第二次临时股东大会、2024 年第二次 A 股 类别股东大会及 2024 年第二次 H 股类别股东大会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 经康龙化成（北京）新药技术股份有限公司（以下简称"公司"）于 2024 年 11 月 27 日召开的第三届董事会第十一次会议审议通过，决定召开公司 2024 年 第二次临时股东大会、2024 年第二次 A 股类别股东大会及 2024 年第二次 H 股 类别股东大会（以下简称"本次股东大会"），现将 A 股股东参与本次股东大会 相关事项通知如下： 一、召开会议的基本情况 1、股东大会届次：2024 年第二次临时股东大会、2024 年第二次 A 股类别 股东大会及 2024 年第二次 H 股类别股东大会 2、股东大会的召集人：公司董事会。 3、会议召开的合法、合规性：本次股东大会的召集、召开程序符合有关法 律、行政法规、部门规章、规范性文件和《公司章程》的规定。 4、会议召开的时 ...

康龙化成（北京）新药技术股份有限公司 独立非执行董事工作制度 第一章 总 则 第一条 为完善康龙化成（北京）新药技术股份有限公司("公司")治理结 构，规范公司运作，更好的维护公司整体利益，保障全体股东特别是中小股东的 合法权益不受损害，根据《中华人民共和国公司法》（"《公司法》"）、中国证券监 督管理委员会（"中国证监会"）、公司股票上市地证券交易所的上市规则(包括但 不限于《香港联合交易所有限公司证券上市规则》（"《上市规则》"）)、和 《康龙化成（北京）新药技术股份有限公司章程》（"《公司章程》"）的规定，制 定《康龙化成（北京）新药技术股份有限公司独立非执行董事工作制度》（"本制 度"）。 第二条 独立非执行董事系指不在公司担任除独立非执行董事外的任何其他 职务，并与公司及其主要股东、实际控制人不存在直接或者间接利害关系，或者 其他可能影响其进行独立客观判断的关系的董事。 独立非执行董事应当独立履行职责，不受公司及其主要股东、实际控制人等 单位或者个人的影响。 独立非执行董事对公司及全体股东负有忠实与勤勉义务，应当按照法律、行 政法规、中国证监会规定、公司股票上市地证券交易所的上市规则和《公司章程》 ...

Investment Rating - The investment rating for the company is "Buy" and is maintained [4]. Core Insights - The company reported a revenue of 8.817 billion yuan for the first three quarters of 2024, representing a year-on-year increase of 3.00%. The net profit attributable to shareholders was 1.422 billion yuan, up 24.82% year-on-year. However, the adjusted net profit under non-IFRS was 1.107 billion yuan, a decrease of 21.60% compared to the same period last year [3][4]. - In Q3, the company achieved a revenue of 3.213 billion yuan, which is a 10.02% increase year-on-year and a 9.51% increase quarter-on-quarter. The adjusted net profit for this quarter was 417 million yuan, down 13.20% year-on-year, but the decline has narrowed [3]. - The revenue breakdown shows that North American clients contributed 5.731 billion yuan (64.99% of total revenue), European clients contributed 1.527 billion yuan (17.32%), Chinese clients contributed 1.329 billion yuan (15.07%), and other regions contributed 230 million yuan (2.62%) [3]. - New orders have shown a continuous recovery, with a year-on-year increase of over 18% in new contracts for the first three quarters of 2024, driven by the gradual recovery of overseas client demand and more services entering mid-to-late clinical development stages [3]. - The company is focusing on CDMO and clinical business as key breakthrough areas while advancing its layout in large molecules and CGT. The integrated platform is becoming increasingly robust, with traditional businesses improving alongside the recovery of overseas markets, and emerging businesses showing promising future potential [3]. Financial Summary - For 2024, the company is projected to achieve net profits of 1.865 billion yuan, 1.816 billion yuan, and 2.105 billion yuan for the years 2024, 2025, and 2026, respectively, corresponding to a PE ratio of 30, 30, and 26 times [3][7]. - The total revenue for 2023 is estimated at 11.538 billion yuan, with a projected increase to 12.051 billion yuan in 2024 and further growth to 15.720 billion yuan by 2026 [7]. - The company’s net profit for 2023 is expected to be 1.582 billion yuan, with projections of 1.832 billion yuan in 2024 and 2.073 billion yuan in 2026 [7]. Market Performance - The current stock price is 30.93 yuan, with a total share capital of 178.739 million shares. The highest and lowest prices in the last 12 months were 37.00 yuan and 17.70 yuan, respectively [4]. - The company’s market performance is benchmarked against the CSI 300 index, with a target of outperforming the index by more than 10% for a "Buy" rating [8].

Investment Rating - The report assigns a "Buy" rating to the company, indicating an expected relative increase of over 15% compared to the CSI 300 index within the next 6 months [1][9] Core Views - The company's 3Q performance showed sequential improvement, with CMC new order growth accelerating [1] - The company's four major business segments are Laboratory Services, CMC Services, Clinical Research Services, and Large Molecule and Cell & Gene Therapy Services [1] - In the first three quarters of 2024, the company achieved revenue of 8.817 billion yuan, a year-on-year increase of 3.0%, and net profit attributable to the parent company of 1.422 billion yuan, a year-on-year increase of 24.8% [1] - The company's new order signings increased by over 18% year-on-year, with CMC new orders growing by over 30% [1][2] Business Segment Analysis Laboratory Services - Contributed 5.219 billion yuan in revenue in the first three quarters of 2024, a 2.95% year-on-year increase, with a gross margin of 44.76% [1] - New orders increased by over 12% year-on-year [1] - The company's drug safety evaluation laboratory passed national GLP certification in July 2024 [1] CMC Services - Generated 1.977 billion yuan in revenue in the first three quarters of 2024, a 3.29% year-on-year increase [1] - Third-quarter revenue reached 801 million yuan, a 34.9% sequential increase and 20.9% year-on-year growth [2] - New orders increased by over 30% year-on-year [2] Clinical Research Services - Achieved 1.306 billion yuan in revenue in the first three quarters of 2024, a 3.48% year-on-year increase [2] - Gross margin declined to 13.20%, down 5.04 percentage points year-on-year [2] Large Molecule and Cell & Gene Therapy Services - Recorded 311 million yuan in revenue in the first three quarters of 2024, a slight 0.11% year-on-year increase [2] - Gross margin was negative at -42.81%, primarily due to ongoing construction and investment phase [2] Financial Performance - The company's comprehensive gross margin for the first three quarters of 2024 was 33.87%, a decrease of 2.09 percentage points year-on-year [1] - Sales net margin increased to 15.53%, up 2.28 percentage points year-on-year [1] - The company's price-to-earnings ratio for 2024-2026 is projected at 31.58x, 28.17x, and 23.77x respectively [3][4] Future Outlook - The company is expected to achieve EPS of 0.98 yuan, 1.10 yuan, and 1.30 yuan for 2024-2026 [3] - Revenue is projected to grow from 12.190 billion yuan in 2024 to 16.302 billion yuan in 2026 [4] - Net profit is forecasted to increase from 1.751 billion yuan in 2024 to 2.326 billion yuan in 2026 [4]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2024年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 康龍化成（北京）新藥技術股份有限公司 (於中華人民共和國註冊成立的股份有限公司） 呈交日期: 2024年11月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03759 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 301,537,125 | RMB | | 1 RMB | | 301,537,125 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 301,537,125 | RMB | | 1 RMB | | 301,537,125 | ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has shown a continuous improvement in new orders, indicating a steady recovery in overall business performance. The growth in new orders is attributed to the gradual recovery of overseas client demand and the advancement of more service projects into the later stages of clinical development [1][2] - The financial forecasts indicate a projected revenue increase from 11,538 million yuan in 2023 to 15,979 million yuan by 2026, reflecting a compound annual growth rate (CAGR) of approximately 15.11% [1][10] - The net profit is expected to grow from 1,601.10 million yuan in 2023 to 2,223.19 million yuan by 2026, with a net profit margin improvement anticipated [1][11] Financial Performance Summary - **Revenue (in million yuan)**: - 2022: 10,266.29 - 2023: 11,538.00 - 2024E: 12,072.30 - 2025E: 13,881.54 - 2026E: 15,979.41 - Year-on-Year Growth Rate: 2023: 12.39%, 2024E: 4.63%, 2025E: 14.99%, 2026E: 15.11% [1] - **Net Profit (in million yuan)**: - 2022: 1,374.60 - 2023: 1,601.10 - 2024E: 1,718.27 - 2025E: 1,876.64 - 2026E: 2,223.19 - Year-on-Year Growth Rate: 2023: 16.48%, 2024E: 7.32%, 2025E: 9.22%, 2026E: 18.47% [1] - **Earnings Per Share (in yuan)**: - 2022: 0.77 - 2023: 0.90 - 2024E: 0.96 - 2025E: 1.05 - 2026E: 1.24 [1] - **Price-to-Earnings (P/E) Ratio**: - 2022: 37.44 - 2023: 32.14 - 2024E: 29.95 - 2025E: 27.42 - 2026E: 23.15 [1] - **Price-to-Book (P/B) Ratio**: - 2022: 4.88 - 2023: 4.10 - 2024E: 3.59 - 2025E: 3.17 - 2026E: 2.79 [1] Market Trends and Order Growth - The company reported a new order growth of over 3.00 billion yuan in the first three quarters of 2024, driven by the recovery of overseas client demand and the expansion of service projects into advanced clinical stages [1][2] - The overall gross margin for the company is expected to stabilize as the business gradually recovers, with a focus on maintaining competitive advantages in integrated and multi-therapy platforms [1][10]

Investment Rating - The report maintains a "Buy" rating for 康龙化成 (300759) [4][3] Core Views - The company shows improvement in gross margin, a continuation of new order growth, and an optimized customer structure, indicating a positive long-term growth outlook [3] - Revenue for Q1-Q3 2024 reached 8.817 billion yuan, up 3.0% year-on-year, with net profit attributable to shareholders at 1.422 billion yuan, up 12.5% [3] - The report adjusts the EPS forecast for 2025-2026 to 1.10 yuan and 1.31 yuan respectively, down from previous estimates of 1.13 yuan and 1.35 yuan, while maintaining the 2024 EPS forecast at 0.98 yuan [3] - The target price is raised to 33.90 yuan from 27.16 yuan, reflecting a valuation premium based on comparable company valuations and the gradual ramp-up of backend business [3] Summary by Sections Financial Performance - Q3 2024 single-quarter revenue was 3.213 billion yuan, up 10.0%, with net profit at 308 million yuan, down 12.62% [3] - Laboratory services revenue for Q1-Q3 2024 was 5.219 billion yuan, up 2.95%, with a gross margin of 44.76% [3] - CMC revenue was 1.977 billion yuan, up 3.29%, with a gross margin of 30.82% [3] - Clinical research services revenue was 1.306 billion yuan, up 3.48%, with a gross margin of 13.20% [3] Order Growth and Customer Structure - New orders for Q1-Q3 2024 increased by over 18% year-on-year, with laboratory services and CMC new orders growing by over 12% and 30% respectively [3] - Revenue from the top 20 global pharmaceutical companies reached 1.293 billion yuan, accounting for 14.66% of total revenue [3] - Revenue from European clients grew by 15.74% to 1.527 billion yuan, while North American clients contributed 5.731 billion yuan, up 4.29% [3] Business Outlook - The report highlights improved operational efficiency and a favorable investment environment, suggesting that backend business development may exceed expectations [3]